دورية أكاديمية
Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy
| العنوان: | Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy |
|---|---|
| المؤلفون: | Venkateswarlu Chamcha, Li He, Jenny Xu, Andrew R. Swartz, Erin Green-Trexler, Kevin Gurney, Tessie McNeely |
| المصدر: | Heliyon, Vol 10, Iss 7, Pp e28414- (2024) |
| بيانات النشر: | Elsevier, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Science (General) LCC:Social sciences (General) |
| مصطلحات موضوعية: | Analytical Method Development, Plaque Assay, TCID50 Assay, Method Qualification, Validation, Vaccine development, Science (General), Q1-390, Social sciences (General), H1-99 |
| الوصف: | Oncolytic viruses (OV) are part of a burgeoning field of investigational oncolytic therapy (OT), in which lytic viruses dissolve advanced tumors productively and specifically. One such OT is a Coxsackievirus A21 (CVA21) based OV that is currently under clinical evaluation. A tissue culture infectious dose (TCID50) assay was used for CVA21 potency release and stability testing in early clinical development. The titer measured in this method was an extrapolated value from cytopathic effect (CPE) observed during the serial dilution but doesn't represent direct viral killing of cells. Moreover, the assay was not deemed to be optimal to carry into late phase clinical development due to limitations in assay precision, turn-around time, and sample throughput. To address these points, we developed a plaque assay to measure viral plaque forming units to measure the potency value for drug substance (DS), drug product (DP) and virus seed (master and working) stocks. In this manuscript, we describe the steps taken to develop this plaque assay for the late-stage clinical development, which include the assay qualification, validation, and robustness protocols, and describe statistical methods for data analysis. Moreover, the method was validated for linearity, accuracy, precision, and specificity. Furthermore, the plaque assay quantifies OV infectivity with better precision (32% vs 58%), with higher sample throughput (22 samples/week vs 3 samples/week) and shorter assay turnaround time (4 days vs 7 days) than the TCID50 method. This assay development strategy can provide guidance for the development of robust cell-based potency methods for OVs and other infectious viral products. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2405-8440 |
| Relation: | http://www.sciencedirect.com/science/article/pii/S2405844024044451; https://doaj.org/toc/2405-8440 |
| DOI: | 10.1016/j.heliyon.2024.e28414 |
| URL الوصول: | https://doaj.org/article/b7edfe1a02654ea582c236ba1499b2d5 |
| رقم الأكسشن: | edsdoj.b7edfe1a02654ea582c236ba1499b2d5 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 24058440 |
|---|---|
| DOI: | 10.1016/j.heliyon.2024.e28414 |